Finance
By: Shree1news, 26 OCT 2021
US pharmaceutical giant Moderna on Monday reported a “robust neutralising antibody response” to its Covid vaccine in children aged 6-11, and mentioned that it’ll submit the trial data to global regulators soon.
Researchers examined two shots for the 6- to 11-year-olds, given a month aside, that each contained half the dose given to adults. Preliminary outcomes confirmed vaccinated children developed virus-fighting antibodies similar to levels that young adults produce after full-strength shots, Moderna mentioned.
Data from clinical trials with more than 4,700 children within the age range “demonstrate strong immune response… one month after the second dose,” Moderna mentioned. It added that like adults, the vaccinated children had temporary side effects including fatigue, headache, fever and injection site pain.
Source:HT
